{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T05:18:58Z","timestamp":1741238338636,"version":"3.38.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-024-00600-w","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:52:11Z","timestamp":1741182731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency"],"prefix":"10.1186","volume":"23","author":[{"given":"F.","family":"Jakobs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Osterkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"600_CR1","unstructured":"Erdmann F, Spix C, Katalinic A et al. Krebs in Deutschland f\u00fcr 2017\/2018. 2021."},{"issue":"10","key":"600_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.clml.2015.06.003","volume":"15","author":"TN Sergentanis","year":"2015","unstructured":"Sergentanis TN, Zagouri F, Tsilimidos G, et al. Risk factors for multiple myeloma: a systematic review of Meta-analyses. Clin Lymphoma Myeloma Leuk. 2015;15(10):563\u2013e577561.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"600_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","volume":"18","author":"J Blad\u00e9","year":"2005","unstructured":"Blad\u00e9 J, Rosi\u00f1ol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol. 2005;18(4):635\u201352.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"600_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000442511","volume":"1","author":"P Yadav","year":"2016","unstructured":"Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis (Basel). 2016;1(4):241\u201357.","journal-title":"Kidney Dis (Basel)"},{"issue":"3","key":"600_CR5","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Cheung MC, Roussel M, et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica. 2016;101(3):363\u201370.","journal-title":"Haematologica"},{"issue":"8","key":"600_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","volume":"8","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV. Treatment of multiple myeloma. Nat Reviews Clin Oncol. 2011;8(8):479\u201391.","journal-title":"Nat Reviews Clin Oncol"},{"key":"600_CR7","unstructured":"European Medicines Agency. Summary of Product Characteristics [Sarclisa]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf. Accessed January 10, 2023."},{"issue":"3","key":"600_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus Pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet. 2022;23(3):416\u201327.","journal-title":"Lancet"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","volume":"35","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Leleu X, Moreau P, et al. Effect of isatuximab plus pomalidomide\/dexamethasone on renal impairment in relapsed\/refractory multiple myeloma: ICARIA-MM study subgroup analysis. Leukemia. 2021;35:562\u201372.","journal-title":"Leukemia"},{"key":"600_CR10","unstructured":"Vereinbarung gem\u00e4\u00df \u00a7 10 Absatz 9 KHEntgG f\u00fcr den Vereinbarungszeitraum. 2022. 2022; https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/krankenhaeuser\/budgetverhandlungen\/bundesbasisfallwert\/KH_BBFW_2022.pdf. Accessed August 21, 2022."},{"key":"600_CR11","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","volume":"38","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Value and cost of Myeloma Therapy. Am Soc Clin Oncol Educ Book. 2018;38:662\u20136.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"600_CR12","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"A Gulla","year":"2020","unstructured":"Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020;105(10):2358\u201367.","journal-title":"Haematologica"},{"issue":"9","key":"600_CR13","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia. 2017;31(9):1915\u201321.","journal-title":"Leukemia"},{"key":"600_CR14","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). Accessed Februar 06, : Diagnostik, Therapie und Nach-sorge f\u00fcr Patienten mit monoklonaler Gammopathie unklarer Signifikanz (MGUS) oder Multiplem Myelom, Langversion 1.0, 2022, AWMF-Registernummer: 018\/035OL, https:\/\/www.leitlinienprogrammonkologie.de\/leitlinien\/multiples-myelom\/. (2023)."},{"issue":"1","key":"600_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Supplements. 2012;2(1):1\u2013138.","journal-title":"Kidney Int Supplements"},{"key":"600_CR16","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. ICD-10-GM Version. 2022: Kapitel XIV Krankheiten des Urogenitalsystems (N00-N99) - Niereninsuffizienz (N17-N19) 2022; https:\/\/www.dimdi.de\/static\/de\/klassifikationen\/icd\/icd-10-gm\/kode-suche\/htmlgm2022\/block-n17-n19.htm. Accessed August 19, 2022."},{"key":"600_CR17","unstructured":"Canadian Agency for Drugs & Technologies in Health (CADTH). CADTH Reimbursement Recommendation - Isatuximab (Sarclisa). 2021; August 21. https:\/\/canjhealthtechnol.ca\/index.php\/cjht\/article\/view\/pc0256\/522. Accessed 2022."}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-024-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-024-00600-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-024-00600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T13:52:14Z","timestamp":1741182734000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-024-00600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s12962-024-00600-w","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"29 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective study design and a pseudonymised documentation of underlying cost data, no ethical vote was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}